Skip to content

Why Subscribe
About Us
Accreditation
Library
Live Events
Sign Up / Login

Why Subscribe
About Us
Accreditation
Library
Live Events
Sign Up / Login

Library

Speciality

Author / Speaker

Title of Presentation

Type of Media

Event

2024 Event

Clear

Displaying 1,451 - 1,475 of 2,711

«
1
…
57
58
59
60
61
…
109
»

RET, MET, and BRAF Mutant Lung Cancer Tumors

RET, MET, and BRAF Mutant Lung Cancer Tumors

By: Edgardo S. Santos Castillero, MD, FACP

Liquid Biopsy: Advances in the Last Decade and Future Directions

Liquid Biopsy: Advances in the Last Decade and Future Directions

By: Edgardo S. Santos Castillero, MD, FACP

Other Targetable Agents (KRASg 12c, BRafv600, RET and NTRK)

Other Targetable Agents (KRASg 12c, BRafv600, RET and NTRK)

By: Edgardo S. Santos Castillero, MD, FACP

Liquid Biopsy: Advances in the Last Decade and Future Directions

Liquid Biopsy: Advances in the Last Decade and Future Directions

By: Edgardo S. Santos Castillero, MD, FACP

Other Targetable Agents (KRASg 12c, BRafv600, RET and NTRK)

Other Targetable Agents (KRASg 12c, BRafv600, RET and NTRK)

By: Edgardo S. Santos Castillero, MD, FACP

EGFR, K-RAS and ERBB2 Mutations in NSCLC

EGFR, K-RAS and ERBB2 Mutations in NSCLC

By: Edgardo S. Santos Castillero, MD, FACP

EGFR, K-RAS and ERBB2 Mutations in NSCLC

EGFR, K-RAS and ERBB2 Mutations in NSCLC

By: Edgardo S. Santos Castillero, MD, FACP

Novel Treatment for Unresectable Stage III NSCLC

Novel Treatment for Unresectable Stage III NSCLC

By: Edgardo S. Santos Castillero, MD, FACP

Novel Treatment for Unresectable Stage III NSCLC

Novel Treatment for Unresectable Stage III NSCLC

By: Edgardo S. Santos Castillero, MD, FACP

Small Cell Lung Cancer

Small Cell Lung Cancer

By: Edgardo S. Santos Castillero, MD, FACP, FASCO

HER-3 as a New Target in NSCLC

HER-3 as a New Target in NSCLC

By: Edgardo S. Santos, MD

HER-3 as a New Target in NSCLC

HER-3 as a New Target in NSCLC

By: Edgardo S. Santos, MD

Liquid Biopsy in the Management of Lung Cancer

Liquid Biopsy in the Management of Lung Cancer

By: Edgardo S. Santos, MD, FACP

EGFR Common and Uncommon Mutations & What Is Next For This Patient Population

EGFR Common and Uncommon Mutations & What Is Next For This Patient Population

By: Edgardo S. Santos, MD, FACP

EGFR & ALK: Where are We Now

EGFR & ALK: Where are We Now

By: Edgardo S. Santos, MD, FACP

New Landscape of Mutant EGFR & ALK Lung Cancer Patients

New Landscape of Mutant EGFR & ALK Lung Cancer Patients

By: Edgardo S. Santos, MD, FACP

RET, MET, & NTRK in Non-Small Cell Lung Cancer

RET, MET, & NTRK in Non-Small Cell Lung Cancer

By: Edgardo S. Santos, MD, FACP

RET, MET, and BRAF Mutant Lung Cancer Tumors

RET, MET, and BRAF Mutant Lung Cancer Tumors

By: Edgardo S. Santos, MD, FACP

Other Driver Mutations: ROS-1, RET, HER-2, MET & Exon 20 Insertions

Other Driver Mutations: ROS-1, RET, HER-2, MET & Exon 20 Insertions

By: Edgardo S. Santos, MD, FACP

Targeted Therapy in Non-Squamous NSCLC: Where Are We and What Is Coming Up?

Targeted Therapy in Non-Squamous NSCLC: Where Are We and What Is Coming Up?

By: Edgardo S. Santos, MD, FACP

EGFR/ALK and ROS-1 Lung Cancer Management

EGFR/ALK and ROS-1 Lung Cancer Management

By: Edgardo S. Santos, MD, FACP

Lung Targeted Therapies IN NSCLC: EGFR, ALK, and ROS1

Lung Targeted Therapies IN NSCLC: EGFR, ALK, and ROS1

By: Edgardo S. Santos, MD, FACP

Advances in Targeted Therapy in Lung Cancer

Advances in Targeted Therapy in Lung Cancer

By: Edgardo S. Santos, MD, FACP

Lung Targeted Therapies IN NSCLC: EGFR, ALK, and ROS1

Lung Targeted Therapies IN NSCLC: EGFR, ALK, and ROS1

By: Edgardo S. Santos, MD, FACP

Advances in Targeted Therapy in Lung Cancer

Advances in Targeted Therapy in Lung Cancer

By: Edgardo S. Santos, MD, FACP

«
1
…
57
58
59
60
61
…
109
»

© 2024 MEC Inc. All rights reserved | Digital Marketing by Katapult Marketing

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok